AVOS Introduces Medicare Drug Benefit Outlooks Reports; Reports Analyze How Medicare Part D Will Affect the Pharmaceutical Industry.RALEIGH, N.C. -- The contact information in release should read: AVOS Life Sciences John Niedermayer, 919-848-2709 JNiedermayer@AvosLifeSciences.com or Maverick Marketing Megan Haney, 919-459-2768 mhaney@maverickmarketing.com sted: AVOS Life Sciences John Niedermayer, 919-459-2768 JNiedermayer@AvosLifeSciences.com or Maverick Marketing Megan Haney, 919-848-2709 mhaney@maverickmarketing.com The corrected release reads: AVOS Avos may refer to the following:
AVOS Life Sciences today announced the availability of Medicare Drug Benefit Outlooks (MDBO), a series of reports that analyze the impact of the Medicare Part D drug benefit on the pharmaceutical industry. Part D was established by the Medicare Prescription Drug prescription drug Prescription medication Pharmacology An FDA-approved drug which must, by federal law or regulation, be dispensed only pursuant to a prescription–eg, finished dose form and active ingredients subject to the provisos of the Federal Food, Drug, , Improvement and Modernization modernization Transformation of a society from a rural and agrarian condition to a secular, urban, and industrial one. It is closely linked with industrialization. As societies modernize, the individual becomes increasingly important, gradually replacing the family, Act of 2003 and goes into effect January 1, 2006. Although this date is fast approaching, significant questions remain regarding the implications of the Part D drug benefit. MDBO examines the scenarios which may play out over the next three years at the product, drug portfolio and company level, taking into account variables such as Part D enrollment and cost containment cost containment, n the features of a dental benefits program or of the administration of the program designed to reduce or eliminate certain charges to the plan. strategies. "This series was born from the need to understand the overall impact of this legislation by the investor community, as well as the pharmaceutical companies themselves," said Neil MacAllister, president of AVOS Life Sciences. "Due to the ambiguity surrounding actual implementation, entities have shied shied 1 v. Past tense and past participle of shy1. shied Verb the past of shy1 or shy2 away from quantifying the potential impact of Part D. Our Medicare Drug Benefit Outlooks directly addresses this lack of analysis." Unlike other analyses that stress the cost of the drug benefit to the taxpayer, MDBO projects revenue forecasts for individual products during the critical time period from 2006 to 2008. This approach allows AVOS to quantify the impact of the drug benefit on each major pharmaceutical company. The framework behind the reports includes the provisions set forth in the legislation, as well as therapeutic and public policy dimensions. As guidelines guidelines, n.pl a set of standards, criteria, or specifications to be used or followed in the performance of certain tasks. change and the legislation is implemented, AVOS will update the series to continue to provide competitive intelligence to the pharmaceutical and investment communities. "Based upon our analysis, there are some clear winners - and some clear losers - in the Part D environment," continued MacAllister. "In the long term, this legislation has great potential to significantly alter the competitive landscape of the pharmaceutical industry." About AVOS Life Sciences, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control AVOS is a boutique advisory and research products firm located in Raleigh, NC, and New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY. We specialize in developing and maintaining a leading-edge understanding of the evolving healthcare environment to help our clients position themselves to win in the future. Our unique capabilities are exemplified through AVOS Signals, a research product suite created to provide insight and guidance in product revenue forecasting, future stock performance and exposure to major industry trends. AVOS also offers consulting services Noun 1. consulting service - service provided by a professional advisor (e.g., a lawyer or doctor or CPA etc.) service - work done by one person or group that benefits another; "budget separately for goods and services" where our experts work closely with client teams to respond to specific business needs. For additional information, please visit www.avoslifesciences.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion